ADCT - ADC Therapeutics SA

ADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland.

52W High

$3.97

52W Low

$1.05

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

2.01

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-1.43

EV/Revenue (<3 favorable)

2.80

P/S (TTM) (<3 favorable)

4.70

P/B (<3 favorable)

2.58

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

19.03%

Institutions (25–75% balanced)

64.57%

Shares Outstanding

112,499,000

Float

92,479,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

77,246,000

Gross Profit (TTM)

-37,506,000

EPS (TTM)

-1.55

Profit Margin (>10% good)

-2.20%

Operating Margin (TTM) (higher better)

-1.65%

ROE (TTM) (>15% strong)

-7.06%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.08

Momentum

Bearish momentum

Value

0.1073

0.1149

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025